title: A phase II, multicentre, UK study of vinorelbine in advanced breast cancer.
abstract: Thirty-four evaluable patients were treated with vinorelbine, a novel, semisynthetic vinca alkaloid, as first-line chemotherapy for advanced breast cancer. They received vinorelbine 25 mg m-2 i.v. given weekly for a maximum of 16 cycles. Two patients achieved a complete remission and 15 a partial remission, giving a response rate of 17/34 (50%; 95% CI of 34-66%); median response duration was 5.8 months. The median progression-free interval was 4.4 months and median survival 9.9 months. Treatment was generally well tolerated. Fatigue was the most common side-effect. The main reason for dose adjustments was myelosuppression; 68% of patients had WHO grade 3 or 4 neutropenia and there was one death attributed to neutropenic sepsis. Nausea/vomiting and neuropathy were mild and alopecia was uncommon. This study confirms vinorelbine as a highly active, well-tolerated agent in advanced breast cancer worthy of evaluation in combination chemotherapy regimens.
authors.affiliation: Imperial Cancer Research Fund Clinical Oncology Unit, UMDS, Guy's Hospital, London, UK.
authors.forename: C J
authors.initials: CJ
authors.lastname: Twelves
authors.forename: N A
authors.initials: NA
authors.lastname: Dobbs
authors.forename: A
authors.initials: A
authors.lastname: Curnow
authors.forename: R E
authors.initials: RE
authors.lastname: Coleman
authors.forename: A L
authors.initials: AL
authors.lastname: Stewart
authors.forename: C J
authors.initials: CJ
authors.lastname: Tyrrell
authors.forename: P
authors.initials: P
authors.lastname: Canney
authors.forename: R D
authors.initials: RD
authors.lastname: Rubens
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D018567:Breast Neoplasms, Male / Q000188:drug therapy; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D014747:Vinblastine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000077235:Vinorelbine
chemical_list: D000970:Antineoplastic Agents; D014747:Vinblastine; D000077235:Vinorelbine